Immutep has signed a clinical trial collaboration and supply agreement with Merck to conduct a Phase II trial, examining the combination of eftilagimod alpha (efti or IMP321) with Keytruda (pembrolizumab) for the treatment of different types of solid tumours.

The proposed Two ACTive Immunotherapies (TACTI-002) trial is designed to analyse safety and efficacy of the efti and Keytruda combination in patients with non-small cell lung cancer (NSCLC), head and neck cancer, or ovarian cancer.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It will be a Simon two-stage study enrolling up to 120 patients across the three indications at various medical centres in Europe and the US.

“This new Phase II clinical trial significantly builds on the momentum we are delivering in the evaluation of efti in cancer.”

The trial is expected to begin in the second half of this year.

Immutep CEO Marc Voigt said: “This clinical trial will evaluate a novel combination of two complementary immuno-oncology treatments in three cancer indications simultaneously, which could lead to more rapid drug development subject to successful outcomes.

“The data generated thus far from our ongoing TACTI-mel clinical trial has supported our hypothesis that there is a compelling therapeutic synergy in administering efti in combination with another immuno-oncology treatment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This new Phase II clinical trial significantly builds on the momentum we are delivering in the evaluation of efti in cancer, with two Phase I clinical trials and now two Phase II clinical trials in our programme for 2018.”

IMP321 is Immutep’s lead immunotherapy product candidate, while Keytruda is Merck’s anti-PD-1 therapy.

Last November, the European Patent Office allowed the use of IMP321 in combination with a chemotherapeutic agent for the treatment of cancer.